Executive Summary
PCC Rokita SA manufactures and distributes chemical products in Poland.
Snowflake
Fair value second-rate dividend payer.
Similar Companies
Share Price & News
How has PCC Rokita's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PCR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.8%
PCR
-2.0%
PL Chemicals
-1.8%
PL Market
1 Year Return
-41.7%
PCR
-8.0%
PL Chemicals
-3.3%
PL Market
Return vs Industry: PCR underperformed the Polish Chemicals industry which returned -8% over the past year.
Return vs Market: PCR underperformed the Polish Market which returned -3.3% over the past year.
Shareholder returns
| PCR | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.8% | -2.0% | -1.8% |
| 30 Day | -3.6% | -3.4% | -1.0% |
| 90 Day | -8.0% | -8.0% | 1.9% |
| 1 Year | -35.9%-41.7% | -5.0%-8.0% | -0.2%-3.3% |
| 3 Year | -5.6%-26.7% | -34.2%-40.5% | 12.4%4.1% |
| 5 Year | 113.6%42.6% | -25.4%-34.7% | 0.9%-11.5% |
Price Volatility Vs. Market
How volatile is PCC Rokita's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Can PCC Rokita SA's (WSE:PCR) ROE Continue To Surpass The Industry Average?3 weeks ago | Simply Wall St
Calculating The Fair Value Of PCC Rokita SA (WSE:PCR)1 month ago | Simply Wall St
Did You Miss PCC Rokita's (WSE:PCR) 44% Share Price Gain?Valuation
Is PCC Rokita undervalued compared to its fair value and its price relative to the market?
4.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PCR (PLN48.6) is trading below our estimate of fair value (PLN50.83)
Significantly Below Fair Value: PCR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PCR is good value based on its PE Ratio (6x) compared to the Chemicals industry average (11.3x).
PE vs Market: PCR is good value based on its PE Ratio (6x) compared to the Polish market (10.5x).
Price to Earnings Growth Ratio
PEG Ratio: PCR is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: PCR is overvalued based on its PB Ratio (1.4x) compared to the PL Chemicals industry average (0.7x).
Next Steps
Future Growth
How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
1.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCR's forecast earnings growth (1.9% per year) is below the savings rate (2.9%).
Earnings vs Market: PCR's earnings (1.9% per year) are forecast to grow slower than the Polish market (11% per year).
High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PCR's revenue (3.2% per year) is forecast to grow slower than the Polish market (5.7% per year).
High Growth Revenue: PCR's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PCR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has PCC Rokita performed over the past 5 years?
26.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCR has high quality earnings.
Growing Profit Margin: PCR's current net profit margins (10.7%) are lower than last year (15.6%).
Past Earnings Growth Analysis
Earnings Trend: PCR's earnings have grown significantly by 26.2% per year over the past 5 years.
Accelerating Growth: PCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PCR had negative earnings growth (-25.5%) over the past year, making it difficult to compare to the Chemicals industry average (33.1%).
Return on Equity
High ROE: Whilst PCR's Return on Equity (23.42%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is PCC Rokita's financial position?
Financial Position Analysis
Short Term Liabilities: PCR's short term assets (PLN424.5M) do not cover its short term liabilities (PLN466.8M)
Long Term Liabilities: PCR's short term assets (PLN424.5M) do not cover its long term liabilities (776.5M)
Debt to Equity History and Analysis
Debt Level: PCR's debt to equity ratio (121.8%) is considered high.
Reducing Debt: PCR's debt to equity ratio has increased from 51.1% to 121.8% over the past 5 years.
Debt Coverage: PCR's debt is well covered by operating cash flow (35.4%).
Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (10.3x coverage).
Balance Sheet
Inventory Level: PCR has a high level of physical assets or inventory.
Debt Coverage by Assets: PCR's debt is not covered by short term assets (assets are 0.5x debt).
Next Steps
Dividend
What is PCC Rokita's current dividend yield, its reliability and sustainability?
17.10%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: PCR's dividend (17.1%) is higher than the bottom 25% of dividend payers in the Polish market (2.68%).
High Dividend: PCR's dividend (17.1%) is in the top 25% of dividend payers in the Polish market (7.36%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, PCR has been paying a dividend for less than 10 years.
Growing Dividend: PCR's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (102.8%), PCR's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PCR's dividends in 3 years are forecast to be well covered by earnings (29.1% payout ratio).
Next Steps
Management
What is the CEO of PCC Rokita's salary, the management and board of directors tenure and is there insider trading?
zł1m
CEO Compensation
CEO
Wieslaw Klimkowski 0
0yrs
Tenure
zł1,346,498
Compensation
Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski serves as President of the Management Board and Director of Investor Superv ...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD0.00) is about average for companies of similar size in the Polish market ($USD0.00).
Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Wieslaw Klimkowski
President of the Mgmt Board
- Tenure: 0yrs
- Compensation: zł1.35m
Marcin Suchanek
Acting MD of the Energy Business Unit & Purchasing Director
- Tenure: 0yrs
Rafal Zdon
VP of the Management Board & Financial Director
- Tenure: 9.8yrs
- Compensation: zł1.24m
Robert Pabich
Secretary of the Supervisory Board & Member of Supervisory Board
- Tenure: 3.7yrs
- Compensation: zł48.00k
Board Members
Alfred Pelzer (59yo)
Chairman of the Supervisory Board
- Tenure: 0yrs
Waldemar Preussner (59yo)
Deputy Chairman of Supervisory Board
- Tenure: 0yrs
Mariusz Dopierala
Member of Supervisory Board
- Tenure: 0yrs
- Compensation: zł46.00k
Robert Pabich
Secretary of the Supervisory Board & Member of Supervisory Board
- Tenure: 3.7yrs
- Compensation: zł48.00k
Arkadiusz Szymanek
Member of Supervisory Board
- Tenure: 1.9yrs
Company Information
PCC Rokita SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PCC Rokita SA
- Ticker: PCR
- Exchange: WSE
- Founded:
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: zł984.724m
- Shares outstanding: 19.85m
- Website: https://www.pcc.rokita.pl
Location
- PCC Rokita SA
- ul. Sienkiewicza 4
- Brzeg Dolny
- 56-120
- Poland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PCR | WSE (Warsaw Stock Exchange) | Yes | Bearer Shares | PL | PLN | Jun 2014 |
| 0QVX | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | PLN | Jun 2014 |
Biography
PCC Rokita SA manufactures and distributes chemical products in Poland. The company offers chloralkali, raw materials, and intermediates; polyurethanes, including flame retardants, polyurethane systems, an ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/22 21:49 |
| End of Day Share Price | 2019/11/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.